PRCT Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -35.93% compared to PROCEPT BioRobotics's net margin of --. PROCEPT BioRobotics's return on equity of -37.42% beat Perspective Therapeutics's return on equity of --.

PROCEPT BioRobotics has a consensus price target of $102.75, signalling upside risk potential of 22.73%. On the other hand Perspective Therapeutics has an analysts' consensus of $16.15 which suggests that it could grow by 396.92%. Given that Perspective Therapeutics has higher upside potential than PROCEPT BioRobotics, analysts believe Perspective Therapeutics is more attractive than PROCEPT BioRobotics.

PROCEPT BioRobotics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

PROCEPT BioRobotics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PROCEPT BioRobotics pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

PROCEPT BioRobotics quarterly revenues are $58.4M, which are larger than Perspective Therapeutics quarterly revenues of --. PROCEPT BioRobotics's net income of -$21M is lower than Perspective Therapeutics's net income of -$15.1M. Notably, PROCEPT BioRobotics's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PROCEPT BioRobotics is 21.50x versus 17.55x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical has a net margin of -35.93% compared to PROCEPT BioRobotics's net margin of 27.73%. PROCEPT BioRobotics's return on equity of -37.42% beat Intuitive Surgical's return on equity of 15.9%.

PROCEPT BioRobotics has a consensus price target of $102.75, signalling upside risk potential of 22.73%. On the other hand Intuitive Surgical has an analysts' consensus of $556.42 which suggests that it could grow by 3.61%. Given that PROCEPT BioRobotics has higher upside potential than Intuitive Surgical, analysts believe PROCEPT BioRobotics is more attractive than Intuitive Surgical.

PROCEPT BioRobotics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.383, suggesting its more volatile than the S&P 500 by 38.272%.

PROCEPT BioRobotics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PROCEPT BioRobotics pays -- of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend.

PROCEPT BioRobotics quarterly revenues are $58.4M, which are smaller than Intuitive Surgical quarterly revenues of $2B. PROCEPT BioRobotics's net income of -$21M is lower than Intuitive Surgical's net income of $565.1M. Notably, PROCEPT BioRobotics's price-to-earnings ratio is -- while Intuitive Surgical's PE ratio is 86.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PROCEPT BioRobotics is 21.50x versus 24.62x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

RxSight has a net margin of -35.93% compared to PROCEPT BioRobotics's net margin of -17.95%. PROCEPT BioRobotics's return on equity of -37.42% beat RxSight's return on equity of -14.78%.

PROCEPT BioRobotics has a consensus price target of $102.75, signalling upside risk potential of 22.73%. On the other hand RxSight has an analysts' consensus of $58.00 which suggests that it could grow by 68.26%. Given that RxSight has higher upside potential than PROCEPT BioRobotics, analysts believe RxSight is more attractive than PROCEPT BioRobotics.

PROCEPT BioRobotics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison RxSight has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

PROCEPT BioRobotics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. RxSight offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PROCEPT BioRobotics pays -- of its earnings as a dividend. RxSight pays out -- of its earnings as a dividend.

PROCEPT BioRobotics quarterly revenues are $58.4M, which are larger than RxSight quarterly revenues of $35.3M. PROCEPT BioRobotics's net income of -$21M is lower than RxSight's net income of -$6.3M. Notably, PROCEPT BioRobotics's price-to-earnings ratio is -- while RxSight's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PROCEPT BioRobotics is 21.50x versus 10.15x for RxSight. Usually stocks with elevated PS ratios are considered overvalued.

Teleflex has a net margin of -35.93% compared to PROCEPT BioRobotics's net margin of 14.52%. PROCEPT BioRobotics's return on equity of -37.42% beat Teleflex's return on equity of 5.32%.

PROCEPT BioRobotics has a consensus price target of $102.75, signalling upside risk potential of 22.73%. On the other hand Teleflex has an analysts' consensus of $238.68 which suggests that it could grow by 34.65%. Given that Teleflex has higher upside potential than PROCEPT BioRobotics, analysts believe Teleflex is more attractive than PROCEPT BioRobotics.

PROCEPT BioRobotics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Teleflex has a beta of 1.156, suggesting its more volatile than the S&P 500 by 15.641%.

PROCEPT BioRobotics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Teleflex offers a yield of 0.77% to investors and pays a quarterly dividend of $0.34 per share. PROCEPT BioRobotics pays -- of its earnings as a dividend. Teleflex pays out 17.93% of its earnings as a dividend. Teleflex's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

PROCEPT BioRobotics quarterly revenues are $58.4M, which are smaller than Teleflex quarterly revenues of $764.4M. PROCEPT BioRobotics's net income of -$21M is lower than Teleflex's net income of $111M. Notably, PROCEPT BioRobotics's price-to-earnings ratio is -- while Teleflex's PE ratio is 35.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PROCEPT BioRobotics is 21.50x versus 2.77x for Teleflex. Usually stocks with elevated PS ratios are considered overvalued.